The US drug-coated balloon market is now competitive. Medtronic PLC announced on January 5 FDA approval of its IN.PACT Admiral paclitaxel-coated balloon for treating peripheral artery disease, primed for a match up with CR Bard Inc.'s first-to-market Lutonix 035.
Bard had an almost three-month head start in the US, launching Lutonix in October. But Medtronic is expected to quickly...